Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict chemo success in colorectal cancer

NCT ID NCT01596790

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new blood test called EPISPOT can predict how well chemotherapy works in people with metastatic colorectal cancer. Researchers measured circulating tumor cells in 168 patients before and during treatment. The goal was to see if early changes in these cells could help doctors personalize therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this blood test could help doctors choose the best first-line treatment for metastatic colorectal cancer patients.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove reliable enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

168 people

The number who actually took part.

Started

Apr 2012

Finished

Sep 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Colon or rectum adenocarcinoma (based on the histology) * Visceral metastases (synchronous and/or metachronous) * Metastatic disease measurable with the RECIST 1.1 criteria * WHO performance status 0, 1 or 2 * Life expectancy\>3 months when starting the treatment * Chemotherapy in metastatic 1rst line combining a protocol of conventional chemotherapy combining 5-FU and IRINOTECAN (FOLFIRI, XELIRI) associated with bevacizumab * Follow-up of at least one year * Collection of the written consent * Social security affiliation Exclusion Criteria: * 2nd line chemotherapy and beyond * History of other cancers considered not cured * Active and progressive infection or other serious disease that may not allow the patient to receive the treatment * refusal to participate * Patient unable to express his consent * Pregnant women * Patient unable to be followed-up for at least one year * Current participation to another clinical trial * Patients under guardianship * Vulnerable people protected by the law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic colorectal cancer

Contacts and locations

Locations

  • Medical Oncology, CHU St Eloi

    Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.